8-K: Panbela Therapeutics Announces ASPIRE Trial Interim Data Analysis Delayed to Q1 2025

Panbela Therapeutics has announced that the interim data analysis for its ASPIRE trial has been pushed to Q1 2025 due to a lower-than-expected event rate, which suggests improved patient survival.

Summary

• Panbela Therapeutics has delayed the interim data analysis for its ASPIRE trial to the first quarter of 2025.
• The delay is due to a lower-than-expected event rate in the trial, indicating that patients are living longer than initially anticipated.
• The ASPIRE trial is evaluating ivospemin (SBP-101) in combination with gemcitabine and nab-paclitaxel for metastatic pancreatic ductal adenocarcinoma (mPDAC).
• The trial requires 33% of total expected events to occur before the interim analysis can be conducted, and less than half of the required events have occurred to date.
• Panbela believes that ivospemin has the potential to significantly improve outcomes for mPDAC patients, beyond the benefits observed with recently approved therapies.
• The company's pipeline includes assets in clinical trials for familial adenomatous polyposis (FAP), metastatic pancreatic cancer, colorectal cancer prevention, and ovarian cancer.
• Ivospemin has previously shown a median overall survival of 14.6 months and an objective response rate of 48% in clinical studies of metastatic pancreatic cancer patients.
• Flynpovi, another of Panbela's assets, has shown statistically significant benefit in delaying surgical events in FAP patients with lower GI anatomy.

Sentiment

Score: 5

Explanation: The document contains both positive and negative elements. The delay in the trial is a negative, but the reason for the delay (improved patient survival) is a positive. The overall sentiment is neutral with a slight negative bias due to the delay.

Positives

• The lower-than-expected event rate in the ASPIRE trial suggests that patients are experiencing prolonged survival, which is a positive sign for the efficacy of ivospemin.
• Ivospemin has shown promising results in previous studies, with a median overall survival of 14.6 months and an objective response rate of 48%.
• Flynpovi has demonstrated a statistically significant benefit in delaying surgical events for FAP patients with lower GI anatomy.
• The company has a pipeline of assets in clinical trials for various cancers, indicating a broad approach to addressing unmet medical needs.

Negatives

• The interim data analysis for the ASPIRE trial has been delayed to Q1 2025, which may push back the timeline for potential regulatory approvals.
• The trial requires 33% of total expected events to occur before the interim analysis can be conducted, and less than half of the required events have occurred to date.

Risks

• The company's ability to obtain additional funding to execute its business and clinical development plans is a risk.
• The progress and success of the clinical development program is uncertain.
• The impact of the COVID-19 pandemic on the ability to conduct clinical trials is a risk.
• The company's ability to demonstrate the safety and effectiveness of its product candidates is a risk.
• The company relies on a third party for the execution of the registration trial for Flynpovi.
• Obtaining regulatory approvals for product candidates in the United States, the European Union, or other international markets is a risk.
• Market acceptance and future sales of product candidates are uncertain.
• Changes in regulatory oversight may result in cost and delays in product development.
• The rate of progress in establishing reimbursement arrangements with third-party payors is a risk.
• Competing technological and market developments are a risk.
• The costs involved in filing and prosecuting patent applications and enforcing or defending patent claims are a risk.
• The company's ability to obtain a listing of its common stock on a national securities exchange is a risk.

Future Outlook

Panbela will continue to monitor the progress of the ASPIRE trial and provide updates as appropriate. The company anticipates sharing the interim results in March 2025.

Management Comments

• Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela Therapeutics, stated that they are encouraged by the lower-than-expected event rate, which suggests that patients in the ASPIRE trial have experienced prolonged survival.
• Dr. Simpson also stated that they believe that the addition of ivospemin (SBP-101) to the standard-of-care regimen has the potential to significantly improve outcomes for patients with mPDAC.

Industry Context

The announcement is set against the backdrop of recent advancements in mPDAC treatment, such as the approval of Onivyde in the NALIRIFOX regimen, which provides a modest survival benefit. Panbela is positioning ivospemin as a potential therapy that could offer more significant improvements in patient outcomes.

Comparison to Industry Standards

• The Napoli 3 trial led to the approval of liposomal irinotecan (Onivyde) in combination with fluorouracil, oxaliplatin and leucovorin (NALIRIFOX), which showed a median overall survival benefit of 1.9 months compared to gemcitabine and nab-paclitaxel.
• The approval of gemcitabine and nab-paclitaxel was based on a median overall survival benefit of 1.8 months over gemcitabine alone.
• Panbela's ivospemin has shown a median overall survival of 14.6 months in previous studies, which exceeds what is typical for the standard of care of gemcitabine + nab-paclitaxel.

Stakeholder Impact

• Shareholders may react negatively to the delay in the interim data analysis.
• Patients with mPDAC may be encouraged by the potential of ivospemin to improve survival outcomes.
• Employees may be impacted by the change in timelines for the ASPIRE trial.

Next Steps

• Panbela will continue to monitor the progress of the ASPIRE trial.
• The company will provide updates as appropriate.
• The interim results are expected to be shared in March 2025.

Key Dates

Keywords

Panbela Therapeutics, ASPIRE trial, ivospemin, SBP-101, metastatic pancreatic cancer, mPDAC, Flynpovi, FAP, clinical trials, interim data analysis